Tables 1

Table 1. Comparative activity of antimicrobial agents against B. fragilis group species*

		B. fragilis			B. distasonis			B. thetaiotamicron			B. ovatus			B. vulgatus
Antibiotic	NCCLS breakpoints^H (S, I)	MIC₅₀	MIC₉₀	Range	MIC₅₀	MIC₉₀	Range	MIC₅₀	MIC₉₀	Range	MIC₅₀	MIC₉₀	Range	MIC₅₀	MIC₉₀	Range
Ticarcillin	(32, 64)	32	128	NA	128	128	NA	64	128	NA	64	128	NA	32	128	NA
Piperacillin	(32, 64)	16	256	NA	64	128	NA	32	128	NA	32	128	NA	64	128	NA
Cefoxitin	(16, 32)	8	32	2 - 256	16	32	4 - 256	8	16	1 - 256	8	16	2 - 64	4	16	2 - 64
Cefotetan	(16, 32)	8	64	2 - 256	128	256	4 - 256	64	256	1 - 256	64	128	2 - 128	4	128	2 - 256
Ceftizoxime	(16, 32)	64	128	4 - 256	32	256	1 - 256	64	256	1 - 256	32	256	4 - 256	16	128	1 - 256
Imipenem	(4, 8)	0.5	0.5	0.015 - 4	0.06	0.25	0.015-0.25	0.5	1	0.03 - 4	0.125	0.25	0.015-0.5	0.25	0.5	0.015-0.5
Meropenem	(4, 8)	0.5	0.5	0.015 - 4	0.06	0.25	0.015-0.25	0.5	1	0.03 - 4	0.125	0.25	0.015-0.5	0.25	0.5	0.015-0.5
Amox /Clavulanate	(4, 8)	1	4	0.25 - 4	2	32	0.125-32	1	2	0.125 - 4	2	8	0.25 - 16	2	8	0.25 - 8
Ampicillin/Sulbactam	(8, 16)	2	8	NA	8	32	NA	4	16	NA	4	16	NA	4	16	NA
Piperacillin/Tazobactam	(32, 64)	0.5	4	NA	8	32	NA	8	16	NA	8	16	NA	8	16	NA
Ticarcillin/Clavulanate	(32, 64)	1	8	NA	16	64	NA	4	16	NA	4	16	NA	2	8	NA
Clindamycin	(2, 4)	0.5	128	0.06-128	2	128	0.06-128	4	128	0.06-128	2	128	0.06-128	0.06	128	0.03-128
Chloram - phenicol^&	(8, 16)	1	8	NA	1	8	NA	1	8	NA	1	8	NA	1	8	NA
Metronidazole	(8, 16)	0.5	0.5	0.25 - 1	0.5	0.5	0.25 - 1	0.5	1	0.25 - 1	0.5	1	0.25 - 1	0.5	0.5	0.25 - 1
Trovafloxacin	(2, 4)	0.25	2	0.25 - 2	0.5	1	0.125 - 1	0.5	2	0.25 - 4	1	2	0.125 - 2	0.25	4	0.125 - 4

* Data based upon various published studies; H, S, I; Susceptible and intermediate breakpoints in μg/ml; I, Not available; &, Drug tested only at screening dilutions

Table 2. Comparative antimicrobial trials for treatment of intra-abdominal and pelvic infections.